Analysts expect GTx, Inc. (NASDAQ:GTXI) to post earnings of ($0.39) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for GTX’s earnings, with the highest EPS estimate coming in at ($0.36) and the lowest estimate coming in at ($0.41). GTX reported earnings per share of ($0.44) in the same quarter last year, which indicates a positive year-over-year growth rate of 11.4%. The business is expected to report its next earnings report on Wednesday, March 21st.

According to Zacks, analysts expect that GTX will report full-year earnings of ($1.61) per share for the current fiscal year, with EPS estimates ranging from ($1.73) to ($1.48). For the next fiscal year, analysts expect that the business will report earnings of ($1.68) per share, with EPS estimates ranging from ($1.69) to ($1.66). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow GTX.

GTX (NASDAQ:GTXI) last posted its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.28) by ($0.25).

Several equities analysts have commented on the stock. Robert W. Baird assumed coverage on shares of GTX in a research note on Tuesday, November 21st. They issued an “outperform” rating and a $17.00 price target for the company. Stifel Nicolaus assumed coverage on shares of GTX in a research note on Thursday, November 9th. They set a “buy” rating for the company.

Several hedge funds have recently modified their holdings of GTXI. Bank of New York Mellon Corp acquired a new position in GTX in the second quarter valued at $124,000. Caxton Corp purchased a new stake in shares of GTX in the third quarter valued at about $531,000. Finally, Abingworth LLP purchased a new stake in shares of GTX in the third quarter valued at about $2,781,000. Hedge funds and other institutional investors own 11.57% of the company’s stock.

GTX (GTXI) traded up $0.18 during trading hours on Thursday, hitting $13.03. 89,693 shares of the company’s stock traded hands, compared to its average volume of 36,496. GTX has a fifty-two week low of $2.73 and a fifty-two week high of $13.35.

TRADEMARK VIOLATION NOTICE: “Analysts Anticipate GTx, Inc. (GTXI) to Post -$0.39 Earnings Per Share” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at

About GTX

GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).

Get a free copy of the Zacks research report on GTX (GTXI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with's FREE daily email newsletter.